Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Amgen Inc.    AMGN


News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Pharmaceutical companies develop system to better track counterfeit drugs

share with twitter share with LinkedIn share with facebook
share via e-mail
02/21/2020 | 11:41am EDT
Logo of U.S. pharmaceutical corporation Pfizer Inc. is seen in Zurich

Some of the industry's largest pharmaceutical companies, including Pfizer Inc and Eli Lilly and Co, have developed a blockchain-based system to track prescription drugs across the supply chain to better halt the flow of counterfeit medicines, company officials said on Friday.

Some two dozen companies in the industry including drugmakers, distributers, retailers and delivery firms created the blockchain-based MediLedger Network, which it has been testing in the verification of drug returns. They said they intend further expand the system this year.

Blockchain, which first emerged as the technology underlying virtual currency bitcoin, is a shared database maintained by a network of computers.

The MediLedger group submitted a report to the U.S. Food and Drug Administration laying out the benefits of blockchain for this specific issue, Susanne Somerville, chief executive officer at technology company Chronicled, told Reuters.

Chronicled is MediLedger's custodian, providing administration of the network.

"We think a blockchain solution can prevent counterfeit medicines," Somerville said in an interview. "The intent is to improve the security of prescription drugs in this country."

Among the 24 participating companies are Amgen Inc , FedEx Corp, GlaxoSmithKline Plc, Novartis, AmerisourceBergen Corp, Sanofi, Walgreens Boots Alliance Inc and Walmart Inc.

Medicines identified as counterfeit may be contaminated, contain the wrong ingredient, or have no active ingredient at all. There have been instances in the past of counterfeit cancer drugs flooding the market, for example.

The World Health Organization estimates that counterfeit medicines worth 73 billion euros (61.12 billion pounds) are traded annually.

"The current point-to-point systems infrastructure lacks the ability to keep data in sync across the healthcare supply chain, which ultimately increases the risk of counterfeit, diverted or otherwise illegitimate products," David Vershure, head of channel and contract management for Roche's Genentech unit, said in a statement.

The core function of the MediLedger Network is to validate the authenticity of drug identifiers throughout the supply chain, the MediLedger report said. This can all be done without any proprietary data being shared openly on the blockchain or ever leaving a company's control.

The MediLedger project was created in response to the FDA's call early last year for pilot projects testing an electronic inter-operable system as outlined in the Drug Supply Chain Security Act (DSCSA).

(Reporting by Gertrude Chavez-Dreyfuss; Editing by Bill Berkrot)

By Gertrude Chavez-Dreyfuss

Stocks mentioned in the article
ChangeLast1st jan.
AMERISOURCEBERGEN CORPORATION 0.14% 88.43 Delayed Quote.2.56%
AMGEN INC. -1.27% 216.17 Delayed Quote.-9.08%
BITCOIN - EURO -1.00% 6715.989 End-of-day quote.5.92%
BITCOIN - UNITED STATES DOLLAR -0.52% 7328.762 End-of-day quote.2.52%
ELI LILLY AND COMPANY -0.58% 145.38 Delayed Quote.11.25%
FEDEX CORPORATION 2.66% 128.99 Delayed Quote.-23.32%
GLAXOSMITHKLINE 2.76% 1541.405 Delayed Quote.-15.72%
NOVARTIS -0.23% 82.07 Delayed Quote.-9.90%
PFIZER, INC. 1.79% 35.15 Delayed Quote.-11.69%
ROCHE HOLDING AG -2.21% 305.05 Delayed Quote.0.67%
SANOFI -1.05% 81.13 Real-time Quote.-8.50%
WALGREENS BOOTS ALLIANCE, INC. 1.69% 43.83 Delayed Quote.-26.92%
WALMART INC. -0.88% 120.76 Delayed Quote.2.52%
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on AMGEN INC.
04/07AMGEN : Can Therapeutic Antibodies Offer Hope for COVID-19 Patients?
04/07AMGEN : And Adaptive Biotechnologies To Participate In Webinar On COVID-19 Strat..
04/02AMGEN : And Adaptive Biotechnologies Announce Strategic Partnership To Develop A..
03/31AMGEN : Establishes Wholly-Owned Affiliate In Japan
03/31AMGEN : 2019 Letter to Shareholders
03/31AMGEN : Update Regarding COVID-19 For Media
03/31AMGEN INC : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-..
03/23AMGEN : Update Regarding COVID-19 For Media
03/23AMGEN : And The Amgen : Foundation Commit Up To $12.5 Million To Support COVID-1..
03/20AMGEN : R&D Head Dr. David Reese Shares Perspective on COVID-19
More news
Financials (USD)
Sales 2020 25 486 M
EBIT 2020 11 861 M
Net income 2020 7 221 M
Debt 2020 19 932 M
Yield 2020 2,90%
P/E ratio 2020 17,6x
P/E ratio 2021 15,3x
EV / Sales2020 5,84x
EV / Sales2021 5,52x
Capitalization 129 B
Duration : Period :
Amgen Inc. Technical Analysis Chart | AMGN | US0311621009 | MarketScreener
Technical analysis trends AMGEN INC.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 29
Average target price 243,15  $
Last Close Price 219,19  $
Spread / Highest target 30,0%
Spread / Average Target 10,9%
Spread / Lowest Target -15,6%
EPS Revisions
Robert A. Bradway Chairman & Chief Executive Officer
Esteban Santos Executive Vice President-Operations
Peter H. Griffith Chief Financial Officer
David M. Reese Executive Vice President-Research & Development
Darryl Sleep Chief Medical Officer & Senior VP-Global Medical
Sector and Competitors
1st jan.Capitalization (M$)
AMGEN INC.-9.08%128 832
JOHNSON & JOHNSON-5.75%377 684
ROCHE HOLDING AG0.67%274 005
MERCK & CO., INC-10.26%206 098
NOVARTIS-9.90%192 476
PFIZER, INC.-11.69%191 948